Key Summary Points {#FPar1}
==================

Extended-spectrum beta-lactamase (ESBL)-producing *E. coli* are the most common cause of community-acquired multidrug-resistant gram-negative bacterial infections.Dissemination of ESBL-producing *E. coli* has been driven by several factors, most notably the expansion of sequence type (ST) 131.This study sought to determine the sequence type (ST) of 369 consecutive clinical isolates of ESBL-producing *E. coli* at a Detroit hospital and compare clinical features of those with ST131 versus non-ST131.96% of ESBL-producing *E. coli* isolates were ST131, suggesting rapid clonal spread of ST 131 *E. coli* at an early period of global dissemination.Clinical characteristics of patients with infections due to ST131 were similar to those with infections due to non-ST131 isolates, though this analysis was limited by the small number of non-ST131 isolates.

Introduction {#Sec1}
============

The number of infections due to multidrug-resistant *Escherichia coli* has increased dramatically in the past 20 years. The emergence of community-acquired infections due to extended-spectrum beta-lactamase (ESBL)-producing *E. coli* began in the late 1990s and has since spread worldwide. Large-scale epidemiologic studies suggest this increase has been largely driven by global expansion of the multilocus sequence type (ST) 131 clone, which is associated with carriage of plasmid-mediated CTX-M beta-lactamase \[[@CR1]--[@CR3]\].

The expansion of the accessary genome, including antimicrobial resistance and virulence genes, along with a wide host range, has contributed to the ST131 *H30* subclone predomination in recent years. The presence of fluoroquinolone resistance mutations in *gyr*A and *par*C, as well as the ESBL and *bla*~CTX~ in ST131, has been associated with delayed time to appropriate antibiotic therapy and prolonged hospital stays \[[@CR4]--[@CR6]\]. Whether ST131 itself is a marker for increased virulence in *E. coli* infections, independent of antibiotic susceptibility, remains unclear \[[@CR7], [@CR8]\].

This study aimed to determine the clinical and molecular epidemiology as well as clinical outcomes of a large cohort of patients with ESBL-producing *E. coli* infections in the context of *E. coli* sequence type. We specifically sought to better characterize the ST distribution in Detroit, MI, during an early phase of the documented ST131 global spread to inform knowledge on the rate of spread in North America and to demonstrate how molecular typing data can provide valuable public health information regarding the epidemiology of resistance dissemination.

Methods {#Sec2}
=======

A retrospective analysis was performed with participant data and bacterial isolates obtained as part of a previously conducted study of patients with ESBL-producing *E. coli* infections admitted from February 2010 through July 2011 at any of eight Detroit Medical Center hospitals \[[@CR9]\]. Approval was obtained from the Wayne State University Institutional Review Board.

Determination of E-Coli Sequence Type and Resistance Genes {#Sec3}
----------------------------------------------------------

ST131 and 2-locus CH-typing were determined using multiplex PCR (CITE) and sequencing of the *fumC* and *fimH* genes \[[@CR10], [@CR11]\]. The presence of ESBL genes *bla*~CTX-M-14~, *bla*~CTX-M-15~, *bla*~SHV~, and *bla*~TEM~ was determined by PCR as part of earlier analyses of these isolates. The antimicrobial susceptibility profile of these isolates was also previously described in the same study \[[@CR9]\].

Data Collection {#Sec4}
---------------

Medical records were reviewed to abstract patient demographics, medical history, and variables relevant to infection severity and clinical course. All instances of potential treatment failure or adverse events were reviewed by a study clinician (M.S.). Effective antibiotic therapy was defined as use of an agent with in vitro activity against the pathogen (according to susceptibility testing performed on Microscan). Timely receipt of effective therapy was defined as effective therapy provided within 48 h of admission.

Statistical Analysis {#Sec5}
--------------------

Variables were compared between ST131 and non-ST131 groups using *χ*^2^ tests for categorical variables and *t* test for continuous measures. Parametric methods (Fisher's exact and Wilcoxon rank sum tests) were used in cases of small numbers. Analyses of treatment outcomes were performed using logistic regression, controlling for timely receipt of effective therapy and patient factors potentially associated with both clonal type and outcome (effective therapy within 48 h, age, sex, Charlson comorbidity score).

Results {#Sec6}
=======

The cohort included 369 individuals with ESBL-producing *E. coli* infections and has been described in detail elsewhere \[[@CR9]\]. The study population had a mean age of 68 years (SD 17.5); 42% were male and 66% African American (*n *= 245) (Table [1](#Tab1){ref-type="table"}). More than half of the subjects resided in nursing facilities and/or had been recently hospitalized; 77.3% of the pathogens were recovered within the first 48 h of hospitalization. The majority of isolates were cultured from the urine (76%; *n *= 281) followed by blood (7%; *n *= 27), sputum (6%; *n *= 24), and wounds (4%, *n *= 14).Table 1Demographic, clinical, and molecular characteristicsPatient characteristicsNon-ST131 (*N* = 15)ST131 (*N* = 351)*P* value\*CategoricalNo./total no. (%)No./total no. (%)Age ≥ 65 years8/15 (53.3)216/350 (61.7)0.49Male5/15 (33.3)146/351 (41.6)0.57Obesity5/15 (33.3)118/350 (33.7)0.95Residence (LTCF/nursing home)7/15 (46.7)180/346 (52.0)0.69 Recent hospitalization6/14 (42.9)197/340 (57.9)0.27ContinuousMedian (IQR)Median (IQR)Age67 (33, 81)69 (57, 81)0.05BMI24 (21, 33)26 (23, 32)0.83LOS total, days7 (1, 9)7 (4, 13)0.62History of present illness/past medical historyCategoricalNo./total no. (%)No./total no. (%)History of nursing care3/12 (25.0)69/232 (29.7)0.84History of urinary tract infection5/12 (41.7)119/311 (38.3)0.77Obstructive urinary diseases2/12 (16.7)34/332 (10.2)0.30Urolithiasis0/12 (0)15/331 (4.50)0.82Hemodialysis1/12 (8.30)21/333 (6.30)0.41Past urologic procedure0/12 (0)24/334 (7.20)0.86Past invasive procedure1/12 (8.30)76/338 (22.5)0.40Past surgery3/13 (23.1)78/337 (23.1)0.86Hemiplegia0/12 (0)49/333 (14.7)0.74Diabetes mellitus4/13 (30.8)144/349 (42.4)0.46ContinuousMedian (IQR)Median (IQR)Weighted Charlson score1.00 (1.00, 3.75)3.00 (2.00, 5.00)0.08Combined comorbidity score5.00 (1.00, 7.00)6.00 (4.00, 8.00)0.08Resistance elementNo./total no. (%)No./total no. (%)TEM8 (53.3)156 (44.4)0.50SHV2 (13.3)31 (8.8)0.36CTX-M (any)9 (60.0)301 (85.8)0.01CTX-M-145 (33.3)46 (13.1)0.02CTX-M-154 (26.7)276 (78.6)\< 0.01*LTCF* long-term care facility, *BMI* body mass index, *LOS* length of stay, *UTI* urinary tract infection, *IQR* interquartile range\*Probability values derived from univariate bias-corrected logistic regression

A total of 351 ST131 isolates were identified (96%). Among the 313 ST131 isolates tested by CH typing, H30 was the most common subclone (*n *= 249; 80%) (Table [2](#Tab2){ref-type="table"}). While the resistance element CTX-M-15 was identified more often among ST131 isolates, it was also found among non-ST131 isolates. CTX-M-14 was present more frequently in non-ST131 isolates (Table [1](#Tab1){ref-type="table"}). Multiple ESBL types were identified in 137 ST131 isolates.Table 2*fumC/fimH* (CH) alleles of ESBL-Producing*E. coli* IsolatesCH typeNon-ST131ST131*04-02*10*04-142*01*04-27*01*04-29*01*04-30*02*04-305*01*04-58*01*103-30*01*103-74*01*106-30*01*106-54*10*11-54*01*13-06*01*13-30*01*14-02*02*14-30*01*14-54*01*187-95*01*23-30*01*26-05*01*26-30*01*26-65*10*35-27*02*37-27*01*37-29*02*38-05*10*38-26*10*38-41*02*40-142*01*40-24*10*40-27*04*40-30*0122*45-97*10*88-145*10*Unknown*^a^7196^a^Of 162 with unknown *fumC* allele, 119 (73%) were *fimH* type 30. Of 11 with unknown *fimH* allele, *fumC* types were 11 (*n* = 6), 26 (*n* = 2), 13 (*n* = 1), 19 (*n* = 1), 88 (*n* = 1)

Patient characteristics were largely similar between ST131 and non-ST131 groups (Table [1](#Tab1){ref-type="table"}). Median time to effective therapy was 48 h in the ST131 group and 35 h in the non-ST131 group (*P *= 0.38). A total of 68 individuals were readmitted within 30 days of discharge (18%), and 16 of these admissions were infection related. Twenty individuals died during their hospital admission (5.8%) with five deaths determined to be due to infection. Forty-three percent of patients (*n *= 96) were discharged to a long-term care facility. In unadjusted analyses, outcomes were largely similar between the ST131 and non-ST131 groups \[Supplemental table\]. In a logistic regression, ST131 was not associated with worse outcomes compared to non-ST131 ESBL-producing *E. coli* infections, controlling for effective therapy within 48 h, age, sex, and Charlson comorbidity score. Patients with ST131 infection had lower odds of readmission following discharge, at both 30-day \[AOR 0.43 (95% CI 0.19, 0.99) and 60-day (AOR 0.43 (95% CI 0.18, 0.95\] time points \[Supplemental table\].

Discussion {#Sec7}
==========

An unexpected finding in our study population was the extremely high prevalence of ST131 in our sample of sequentially collected ESBL-producing *E. coli* isolates (96%) during an early point in the rise of worldwide ESBL prevalence, which is much higher than rates reported in other studies. Data from the same time period (2010--2011) from France found that ST131 comprised 20% of ESBL-producing *E. coli* isolates, and data from Chicago found that ST131 comprised 49% of isolates in Chicago \[[@CR12], [@CR13]\]. In the current study, 80% of ST131 samples with fimH sequencing performed had an H allele type of H30, the ST131 subclone that has been most closely associated with fluoroquinolone resistance. This high proportion of ST131/H30 isolates is consistent with other studies from Detroit, which have reported high rates of resistant organisms and newly emergent strains \[[@CR14]--[@CR16]\]. Data utilizing whole-genome sequencing of almost 2000 clinical *E. coli* isolates from the US and Germany during the 2010--2011 period demonstrated that nearly all CTX-M ESBL-producing *E. coli* infections were due to the *H*30-Rx ST131 subclone, which was associated with higher rates of sepsis \[[@CR17]\]. The current data echo this finding of rapid clonal expansion.

We found no increase in the severity of infection or increased occurrence of adverse patient outcomes of patients with ST131 infections compared to those with non-ST131 infections. In fact, patients with ST131 infection were readmitted less often following discharge in both adjusted and unadjusted models, though numbers of non-ST131 infections were small. The lack of differences observed in clinical outcomes between ST131 and non-ST131 populations were possibly due to the small sample size of non-ST131isolates, limiting statistical power \[[@CR18]\]. Additionally, our patient population had higher rates of chronic illness (in both the ST131 and non-ST131 groups) than many prior studies of ESBL-producing *E. coli* infections, with 49% admitted from nursing home or long-term care facility residences, and the average Charlson score was 3.5.

Patients infected with ESBL-producing *E. coli* were generally elderly with multiple comorbidities and significant prior healthcare exposure, including prior LTCF stays and acute care hospitalizations. The current results suggest that elderly patients in skilled nursing facilities or with other recent healthcare exposures should be considered at increased risk for infection due to ST131 *E. coli.* Rates of 30-day readmission, and particularly readmission due to infection, were high. Given that the minority of readmissions were due to infection, the overall readmission rate may be driven by the high level of chronic disease in this population.

These data are limited by the narrowly defined patient group, i.e., hospitalized patients infected with ESBL-producing *E. coli*. However, this allowed for the comparison of patient outcomes within a very specifically characterized phenotypic group, lessening the potential for unmeasured bias between ST131 and non-ST131 groups. Additionally, our use of a multiplex PCR-based assay has potential to produce false-negative results and may miss non-025b subtypes of ST131. All negative results were tested in duplicate, and additional sequencing of the H30 allele in a selection of isolates was performed to reduce the likelihood of false-negative results. While these data are several years old, we believe that the lessons learned from this study are important and applicable to the current study of *E. coli* and other resistant bacteria.

This study identified ESBL production among several non-ST131 *E. coli* strain types. Therefore, the use of ST131 typing alone should not be used to definitively determine resistance patterns. Susceptibility and molecular resistance gene-based assays remain the most effective diagnostic tests in determining optimal antimicrobial therapy for extraintestinal *E. coli* infections. However, strain typing can be useful in helping to understand important epidemiologic characteristics of pathogen and resistance spread.

Conclusion {#Sec8}
==========

Molecular typing of ESBL-producing *E. coli* will continue to help to define population-based patterns of *E. coli* spread. In this study, sequence typing revealed that ST131 dissemination in specific regions of North America likely occurred more rapidly than previously estimated. Outcomes among those patients infected with ST131 were similar to those infected with non-ST131 *E. coli* isolates. These findings underscore the importance of molecular typing to identify early changes in the prevalence of strains with associated antimicrobial resistance genes, regardless of the specific pathogen. Further refinements in the study of *E. coli* population genetics, including clade typing and accessory genome sequencing, will be valuable public health tools to provide insights into the patterns and epidemiology of resistance transmission.
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